KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Bio-Rad Laboratories (BIO) Accumulated Depreciation & Amortization (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Accumulated Depreciation & Amortization for 17 consecutive years, with $165.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 9.1% to $165.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $165.4 million through Dec 2025, up 9.1% year-over-year, with the annual reading at $165.4 million for FY2025, 9.1% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $165.4 million at Bio-Rad Laboratories, up from $151.6 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $1.1 billion in Q2 2023, with the low at $137.3 million in Q4 2022.
  • Average Accumulated Depreciation & Amortization over 5 years is $700.2 million, with a median of $971.9 million recorded in 2021.
  • Peak annual rise in Accumulated Depreciation & Amortization hit 2690.39% in 2021, while the deepest fall reached 0.72% in 2021.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $137.6 million in 2021, then dropped by 0.22% to $137.3 million in 2022, then grew by 6.26% to $145.9 million in 2023, then grew by 3.91% to $151.6 million in 2024, then grew by 9.1% to $165.4 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $165.4 million, $151.6 million, and $145.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.